La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Harvard Bioscience Croissance future
Future contrôle des critères 0/6
Harvard Bioscience devrait augmenter ses bénéfices et son chiffre d'affaires de 83% et de 7.8% par an respectivement. Le BPA devrait croître de de 84.5% par an. Le rendement des capitaux propres devrait être -0.2% dans 3 ans.
Informations clés
83.0%
Taux de croissance des bénéfices
84.5%
Taux de croissance du BPA
Life Sciences croissance des bénéfices | 17.9% |
Taux de croissance des recettes | 7.8% |
Rendement futur des capitaux propres | -0.2% |
Couverture par les analystes | Low |
Dernière mise à jour | 09 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 123 | 2 | 8 | 12 | 1 |
12/31/2025 | 107 | -3 | 4 | 7 | 2 |
12/31/2024 | 98 | -11 | -2 | 1 | 2 |
6/30/2024 | 101 | -11 | 6 | 9 | N/A |
3/31/2024 | 107 | -9 | 11 | 14 | N/A |
12/31/2023 | 112 | -3 | 12 | 14 | N/A |
9/30/2023 | 113 | -3 | 11 | 12 | N/A |
6/30/2023 | 114 | -5 | 7 | 9 | N/A |
3/31/2023 | 115 | -2 | 4 | 5 | N/A |
12/31/2022 | 113 | -10 | 0 | 1 | N/A |
9/30/2022 | 118 | -7 | -3 | -1 | N/A |
6/30/2022 | 121 | -4 | -4 | -3 | N/A |
3/31/2022 | 121 | -6 | -3 | -2 | N/A |
12/31/2021 | 119 | 0 | 0 | 1 | N/A |
9/30/2021 | 117 | -2 | 2 | 4 | N/A |
6/30/2021 | 111 | -3 | 5 | 6 | N/A |
3/31/2021 | 105 | -4 | 6 | 7 | N/A |
12/31/2020 | 102 | -8 | 8 | 9 | N/A |
9/30/2020 | 102 | -7 | 8 | 9 | N/A |
6/30/2020 | 105 | -8 | 9 | 11 | N/A |
3/31/2020 | 112 | -7 | 8 | 9 | N/A |
12/31/2019 | 116 | -5 | 7 | 8 | N/A |
9/30/2019 | 119 | -2 | 8 | 8 | N/A |
6/30/2019 | 120 | 0 | 3 | 4 | N/A |
3/31/2019 | 122 | -1 | 4 | 4 | N/A |
12/31/2018 | 121 | -4 | 2 | 3 | N/A |
9/30/2018 | 109 | -8 | -2 | -1 | N/A |
6/30/2018 | 99 | -8 | 2 | 3 | N/A |
3/31/2018 | 86 | -7 | N/A | 2 | N/A |
12/31/2017 | 77 | -2 | N/A | 1 | N/A |
9/30/2017 | 82 | -3 | N/A | 4 | N/A |
6/30/2017 | 88 | -4 | N/A | 5 | N/A |
3/31/2017 | 96 | -4 | N/A | 5 | N/A |
12/31/2016 | 105 | -4 | N/A | 5 | N/A |
9/30/2016 | 106 | -20 | N/A | 5 | N/A |
6/30/2016 | 107 | -19 | N/A | 2 | N/A |
3/31/2016 | 110 | -18 | N/A | 0 | N/A |
12/31/2015 | 109 | -19 | N/A | 1 | N/A |
9/30/2015 | 111 | -2 | N/A | 0 | N/A |
6/30/2015 | 110 | 0 | N/A | 1 | N/A |
3/31/2015 | 109 | 0 | N/A | 3 | N/A |
12/31/2014 | 109 | 2 | N/A | 4 | N/A |
9/30/2014 | 106 | 2 | N/A | 4 | N/A |
6/30/2014 | 106 | 1 | N/A | 5 | N/A |
3/31/2014 | 105 | 1 | N/A | 5 | N/A |
12/31/2013 | 105 | 1 | N/A | 4 | N/A |
9/30/2013 | 106 | 4 | N/A | 4 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: HBIO devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: HBIO devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: HBIO devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de HBIO ( 7.8% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de HBIO ( 7.8% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: HBIO devrait être non rentable dans 3 ans.